Overview

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Status:
Not yet recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind and parallel group study to compare the pharmacokinetic, pharmacodynamic, safety and immunogenicity of HS-20090 120mg（1.7ml）and Xgeva® in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.